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xtracellular amyloid 
 
 
 
 peptides (A
 
 
 
s) have long been
thought to be a primary cause of Alzheimer’s disease
 
(AD). Now, detection of intracellular neuronal A
 
 
 
1–42
 
accumulation before extracellular A
 
 
 
 deposits questions
the relevance of intracellular peptides in AD. In the present
study, we directly address whether intracellular A
 
 
 
 is toxic
to human neurons. Microinjections of A
 
 
 
1–42
 
 peptide or a
cDNA-expressing cytosolic A
 
 
 
1–42
 
 rapidly induces cell
 
death of primary human neurons. In contrast, A
 
 
 
1–40
 
, A
 
 
 
40–1
 
,
or A
 
 
 
42–1
 
 peptides, and cDNAs expressing cytosolic A
 
 
 
1–40
 
or secreted A
 
 
 
1–42
 
 and A
 
 
 
1–40
 
, are not toxic. As little as a
 
1-pM concentration or 1500 molecules/cell of A
 
 
 
1–42
E
 
peptides is neurotoxic. The nonﬁbrillized and ﬁbrillized
 
A
 
 
 
1–42
 
 peptides are equally toxic. In contrast, A
 
 
 
1–42
 
 peptides
are not toxic to human primary astrocytes, neuronal, and
 
nonneuronal cell lines. Inhibition of de novo protein synthesis
protects against A
 
 
 
1–42
 
 toxicity, indicating that programmed
cell death is involved. Bcl-2, Bax-neutralizing antibodies,
cDNA expression of a p53
 
R273H
 
 dominant negative mutant,
and caspase inhibitors prevent A
 
 
 
1–42
 
-mediated human
neuronal cell death. Taken together, our data directly
demonstrate that intracellular A
 
 
 
1–42
 
 is selectively cytotoxic
to human neurons through the p53–Bax cell death pathway.
 
Introduction
 
Alzheimer’s disease (AD)* is a progressive neurodegenerative
disease of the central nervous system characterized by the
presence of extracellular senile plaques, intraneuronal neu-
rofibrillary tangles (NFTs), and the loss of synapses and neu-
rons. The amyloid 
 
 
 
 peptide (A
 
 
 
) is a major component of
the extracellular senile plaque. A
 
 
 
 naturally arises from the
metabolic processing of the amyloid precursor protein (APP)
in the ER, the Golgi apparatus, or the endosomal–lysosomal
pathway, and most is normally secreted as a 40– (A
 
 
 
1–40
 
) or
42– (A
 
 
 
1–42
 
) amino acid peptide (Martin et al., 1995;
Chyung et al., 1997; Tienari et al., 1997; Lee et al., 1998;
Morishima-Kawashima and Ihara, 1998; Greenfield et al.,
1999; Perez et al., 1999). However, an NH
 
2
 
-terminally
truncated form of A
 
 
 
1–42
 
 (A
 
 
 
42
 
) accumulates in the ER in
aging cell cultures (Greenfield et al., 1999; Yang et al.,
1999). Recently, the presence of intracellular A
 
 
 
42
 
 has been
detected in the brains of individuals with AD or Down’s
syndrome, and in APP transgenic mice and aging monkeys.
In AD brains, the intracellular A
 
 
 
42
 
 accumulates as aggre-
gates or granules in the cytoplasm of neurons (Gouras et al.,
2000; D’Andrea et al., 2001). The accumulation of A
 
 
 
 pre-
cedes the appearance of NFTs and senile plaques and is ob-
served in regions affected early in AD: the hippocampus and
entorhinal cortex. The intracellular A
 
 
 
 does not appear to
be fibrillar, as it is not stained by Bielchowsky silver stain,
Thioflavin S, or Congo red, nor does it require formic acid
treatment for immunostaining (Gouras et al., 2000). In
 
Down’s syndrome brains, accumulation of intracellular A
 
 
 
1–28
 
and A
 
 
 
40
 
 precedes A
 
 
 
42
 
, and these intracellular A
 
 
 
 accumu-
lations precede the appearance of diffuse plaques, senile core
plaques, and NFT formation (Gyure et al., 2001). In aging
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Figure 1. Intracellular A  neurotoxicity in primary human 
neurons. (A). Fluorescent photomicrographs of microinjected 
neurons. Neurons were microinjected with the peptides in DTR 
and incubated 24 h before staining with TUNEL for cell death or 
Hoechst for nuclear stain. (B) Aged A 1–40, A 1–42, A 42–1, and 
A 40–1 peptides (10 nM) were microinjected into the cytosol of 
human neurons and cell death was measured by TUNEL at 1, 2, 4, 
and 16 d after injection. Two-way ANOVAs (dftime   4; dftreatment   
3) followed by Sheffé’s test were performed to determine the
statistical significance between A -injected and control DTR-injected 
neurons. *, P 0.01. (C) Various doses of A 1–42 and A 40–1 were 
injected into human neurons and cell death was determined by 
TUNEL staining at 2, 4, or 16 d after injection. Two-way ANOVAs 
(dftime   2; dftreatment   29) followed by Sheffé’s test were 
performed to determine the statistical significance. *, P   0.01. 
(D) Human neurons were exposed to 10  M extracellular A 1–40, 
A 1–42, and A 40–1 for 24 h and stained with propidium iodide to 
reveal cellular nuclei and TUNEL to reveal cell death. (E) Cell 
death in neurons 24 h after microinjection with pCep4  episomal 
cDNA constructs expressing cytosolic A 1–40 and A 1–42 (cA ) or secreted A 1–40 and A 1–42 (sA ). One-way ANOVA (df   5) followed 
by Sheffé’s test determined a statistically significant difference between the Cep4  construct alone and A 1–42 peptide or Cep4 -cA 1–42 
expression construct. *, P   0.01. For B–E, the data represent the mean   SEM of three independent experiments.
 
intracellular A
 
 
 
 also precedes plaque formation in mutant
APP/presenilin (PS)-1 transgenic mice (Wirths et al., 2001),
accumulates in the APP
 
V717F
 
 mutation where synaptic loss
monkeys, nonfibrillar neuronal and nonneuronal intracellu-
lar A
 
 
 
 precede the deposition of extracellular and fibrillar
A
 
 
 
 (Martin et al., 1994). Furthermore, the accumulation of 
Intracellular A
 
 
 
 toxicity |
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precedes extracellular A
 
 
 
 deposition (Masliah et al., 1996;
Hsia et al., 1999; Li et al., 1999), and is associated with neu-
ronal loss in PS-1 transgenic mice in the absence of extracel-
lular A
 
 
 
 deposition. Although extensive research has been
conducted on the relevance of extracellular A
 
 
 
 deposits in
AD (Selkoe, 1998), the biological significance of the accu-
mulation of intracellular A
 
 
 
 is not known. The early appear-
ance of the intracellular A
 
 
 
42
 
 suggests that it could be the
initial cause of neuronal dysfunction and neuronal loss in
AD. To determine if intracellular A
 
 
 
 may be detrimental to
neurons, we microinjected A
 
 
 
1–40
 
, A
 
 
 
1–42
 
, and control re-
verse peptides A
 
 
 
40–1
 
 and A
 
 
 
42–1
 
 or cDNAs expressing cyto-
solic or secreted A
 
 
 
1–40
 
 and A
 
 
 
1–42
 
 in primary cultures of hu-
man neurons, neuronal, and nonneuronal cell lines. A
 
 
 
1–42
 
was selectively toxic to human neurons. Microinjections of
the A
 
 
 
1–42
 
 peptide in the presence of transcriptional and
translational inhibitors showed that the cytotoxicity of A
 
 
 
1–42
 
required de novo protein synthesis. Because of the known
role of the p53 transcriptionally regulated proapoptotic Bax
protein in neuronal cell death (Xiang et al., 1998), we as-
sessed the effect of the antiapoptotic Bcl-2 protein and Bax
neutralizing antibodies on A
 
 
 
1–42
 
-mediated neurotoxicity.
Both eliminated toxicity. Furthermore, the p53
 
R273H
 
 domi-
nant negative mutant, which prevents transactivation of Bax
expression (Aurelio et al., 2000), eliminated A
 
 
 
1–42
 
 toxicity.
Lastly, caspase-6–, but not caspase-3–type inhibitors, pre-
vented A
 
 
 
1–42
 
 toxicity. We conclude that A
 
 
 
1–42
 
 is selectively
toxic to human neurons through activation of the p53 and
Bax proapoptotic pathway.
 
Results
 
Intracellular A
 
 
 
1–42
 
, but not A
 
 
 
1–40
 
, A
 
 
 
42–1,
 
 or A
 
 
 
40–1
 
, is 
neurotoxic to human neurons
 
To directly determine whether intracellular A
 
 
 
 is toxic to hu-
man neurons, we microinjected aged A
 
 
 
1–40
 
, A
 
 
 
1–42
 
, or the
reverse control peptide A
 
 
 
40–1
 
 into the cytoplasm of primary
cultured human neurons. A
 
 
 
1–42
 
 induces significant cell death
in 60% of microinjected neurons within 24 h of injection
(Fig. 1, A and B). Cell death further increases to 78 and 90%
at 48 and 96 h after injection. However, A
 
 
 
1–40
 
, the control
reverse peptides, A
 
 
 
40–1
 
, A
 
 
 
42–1
 
, or the fluorescent marker dye
Dextran Texas red (DTR), do not affect cell viability for up
to 4 d (Fig. 1 B). After 16 d of injection, only A
 
 
 
1–40
 
 induces
50% cell death. Because we inject 25 pl/shot of a 10-nM con-
centration of peptide, the above results indicate that 0.25 
 
 
 
10
 
 
 
18
 
 moles of A
 
 
 
1–42
 
 delivered into the neuron cytosol is suf-
ficient to induce rapid neuronal death. A 100-fold dilution in
the amount injected still induces 50% cell death in these neu-
rons (Fig. 1 C). Using confocal microscopy, we estimated the
volume of these human neurons at 4.97 
 
 
 
 0.8 nl (
 
n 
 
  
 
3).
The nuclei occupy 
 
 
 
50% of the cell, thus the cytosolic area is
 
 
 
2.5 nl. Therefore, the actual toxic concentration of injected
A
 
 
 
1–42
 
 is 0.25 
 
 
 
 10
 
 
 
18
 
 to 0.25 
 
 
 
 10
 
 
 
20
 
 moles/2.5 nl, which
equals 10
 
 10 to 10
 12 M, or 1 to 100 pM. These neurons do
not undergo cell death even with 10  M of extracellular A 1–42,
A 1–40, or A 40–1, a concentration known to induce cell
death in a variety of neuronal cell lines (Paradis et al., 1996;
Klein et al., 2001). To test if this particular batch of peptide
might be neurotoxic, we treated the neurons with 10  M of
these peptides for 24 h. Neither extracellular aged A 1–40,
A 1–42, or A 40–1 are toxic to these neurons after 24 h of
treatment (Fig. 1 D). Therefore, the toxicity of intracellular
A 1–42 is at least 100,000 times greater than extracellular
A . These results indicate that an infinitesimal amount of
intracellular A 1–42 is detrimental to human neurons. Cal-
culation of the number of molecules of A 1–42 injected in
neurons based on the Avogadro number shows maximal
toxicity with 150,055 molecules and 50% toxicity with
1505.5 molecules/neuron. The level of toxic A 1–42 is
probably at least 10,000-fold lower than the amount of im-
munologically detectable intracellular A 1–42 in AD neu-
rons. However, because neurons in the brain are bathed in
extracellular milieu that promotes their survival, the in vivo
neurons may resist higher concentrations of intracellular
A 1–42 than the neurons in culture. Finally, to confirm the
toxicity of naturally produced intracellular A  peptides,
neurons were microinjected with cDNA constructs express-
ing cytosolic or secreted A 1–40 and A 1–42. As observed
with the synthetic A 1–42 peptide, only the cytosolically ex-
pressed A 1–42 was toxic, whereas secreted A 1–42 or cytoso-
lic or secreted A 1–40 did not induce cell death in neurons
(Fig. 1 E).
Nonfibrillized A 1–42 is neurotoxic
Because the fibrillar form of A  is commonly seen in the senile
plaques in AD brains and has long been proposed to be more
toxic than soluble A  (Pike et al., 1993), we examined the tox-
icity of both fibrillized and nonfibrillized A  peptides. Trans-
mission electron microscopy on the preparation of A  confirms
the fibrillar and nonfibrillar nature of the A  preparation (Fig.
2 A). The nonfibrillized A 1–42 peptides show well defined
globular as well as diffuse aggregate morphology. Similar well-
defined globular structures are also seen in the nonfibrillized
A 1–40 preparation, but are much less abundant than in the
A 1–42 preparation. The fibrillized A 1–42 peptide shows a het-
erogeneous mixture of fibrils of various sizes, protofibrils, and
globular structures. The fibrils in the A 1–40 preparation were
less heterogeneous and consisted of thick fibrillar aggregates and
thin aligned fibrils. The large A 1–40 fibrils appear not to pass
through the micropipette, and thus were unlikely to have been
injected in neurons (unpublished data). However, some of the
smaller fibrils from the A 1–42 and A 1–40 preparation did pass
through the pipette. Both fibrillized and nonfibrillized prepara-
tions of A 1–42 induce 50–90% neuronal cell death between
24–96 h after injection (Fig. 2 B). In contrast, neither fibrillized
nor nonfibrillized A 1–40 cause significant cell death. Previously,
it was shown that dimers/oligomers of A  are toxic to neurons
when applied in the extracellular milieu (Walsh et al., 1999).
Western blot analysis of the nonfibrillized and fibrillized A 
peptides shows that the A 1–42 peptide forms aggregates with
the expected size of A  dimers, trimers, and oligomers. In con-
trast, the nonfibrillized and fibrillized A 1–40 peptides show a
6.5-kD aggregate and with longer exposure, a smear of higher
MW oligomers (unpublished data). Taken together, these data
show that the fibrils are not required for toxicity and suggest
that either the monomeric A 1–42 is significantly more toxic
than the monomeric A 1–40 or the dimers, trimers, and oligo-
mers of the nonfibrillized and fibrillized A 1–42 peptide may be
the toxic forms of the A  peptides.522 The Journal of Cell Biology | Volume 156, Number 3, 2002
Intracellular A 1–42 toxicity appears selective to 
human neurons
Because neurons specifically undergo cell death in AD, we
explored the specificity of intracellular A  toxicity in pri-
mary cultured human astrocytes. The volume of these cells
is 10 times that of human neurons, therefore, we injected
100 nM of A 1–42 into the cytosol of astrocytes to keep the
same concentration of injected A . In human neurons, cell
death is easily observed in the DTR-microinjected cells by
TUNEL and condensed nuclear DNA (Fig. 3 A). In con-
trast, microinjected astrocytes do not show any sign of con-
densed chromatin by Hoechst staining, nor positive nuclear
TUNEL staining (Fig. 3 A). The faint green fluorescence de-
tected in these cells is the result of bleed-through from the
Figure 2. Soluble and fibrillar A 1–42 are toxic to human neurons. (A) Electron micrographs of nonfibrillized (nf) and fibrillized (f) A 1–40 and 
A 1–42. In the A 1–40 nf, the arrows point to the rare globular structures while in the A 1–40 f, the arrows point to the small aligned fibrils. (B) 
Nonfibrillized or fibrillized A 1–40 or A 1–42 (10 nM) were injected into human neurons and neuronal cell death assessed by TUNEL staining 
at 24, 48, and 96 h after injection. The data represent the mean   SEM of three independent experiments. One-way ANOVA (df   14) followed 
by Sheffé’s test were performed to determine the statistical significance between A -injected and control DTR-injected neurons. *, P   0.01. 
(C) Western blot analysis of fibrillized or nonfibrillized A 1–40 and A 1–42 with 6E10. M, D, and T represent the monomeric, dimeric and trimeric 
forms, respectively. A longer exposure revealed a smear also in the fibrillized A 1–40 (unpublished data).Intracellular A  toxicity | Zhang et al. 523
red DTR fluorescence on our microscope. Similarly, micro-
injections of the A 1–42 peptide into human neuroblastoma,
La-N-1 and M17 cell lines, teratocarcinoma NT2 cells, mice
NIH 3T3 fibroblasts, and BHK cells fail to induce cell
death. Quantitative analysis on 600 microinjected cells from
three independent experiments confirms that among the cell
lines tested, only human primary neurons are susceptible to
the intracellular A 1–42 toxicity (Fig. 3 B). Whether this tox-
icity occurs in vivo in adult human neurons remains to be
determined. However, the in vivo intracellular toxicity of
A 1–42 occurs in transgenic animals (LaFerla et al., 1995).
Taken together, our data demonstrates that intracellular
A 1–42 is selectively toxic to these human neurons.
A 1–42 neurotoxicity requires do novo protein synthesis
To address the underlying molecular mechanism of intracel-
lular A  toxicity, we microinjected A 1–42 into neurons and
incubated the cells in the presence or absence of the tran-
scriptional inhibitor, actinomycin D, and the translational
inhibitor, cycloheximide, for 24 h. Both cycloheximide and
actinomycin D efficiently block A 1–42-induced neuronal
death (Fig. 4). These results indicate that de novo protein
synthesis is necessary for intracellular A  toxicity.
Bax is responsible for intracellular A  toxicity
Because the proapoptotic Bax protein can induce rapid hu-
man neuronal cell death through overexpression (Bounhar et
al., 2001), we suspected that Bax could be involved in A 1–42-
mediated cell death. Therefore, we microinjected a human
cDNA expression construct of Bcl-2, the major anti-Bax
protein, with the A 1–42 peptide (Fig. 5 A). The microinjec-
tion of the Bcl-2 construct completely eliminates A 1–42-
mediated neurotoxicity as observed before against Bax
(Bounhar et al., 2001). In contrast, coinjection of an APP
cDNA construct does not alter A 1–42-mediated cell death.
To confirm that Bax is involved, we tested whether anti-
bodies against human Bax could neutralize Bax-mediated
killing. We found that two monoclonal antibodies, 6A7 and
2D2, and the polyclonal antisera N-20, but not an anti-APP
Figure 3. Intracellular A 1–42 is not toxic to primary human 
astrocytes, neuroblastoma, teratocarcinoma, fibroblast, and kidney 
cell lines. (A) Cells were microinjected with 100 nM A 1–42 and 
DTR and incubated for 24 h. TUNEL staining identified cell death 
and Hoechst staining detected nuclei. (B) Cell survival quantitation 
in several cell lines injected with DTR and A 1–40, A 1–42, or A 40–1 
and incubated 24 h. The data represent the mean   SEM of three 
independent experiments. One-way ANOVA (df   27) followed by 
Sheffé’s test determined the statistical significance between A -injected 
and control DTR-injected cells. *, P   0.01.
Figure 4. Intracellular A 1–42 toxicity requires de novo protein 
synthesis. Neuronal cell death in non or A 1–42 -injected neurons 
incubated in the absence ( ) or presence of 5  g/ml cycloheximide 
(CHX) or 5  M actinomycin D (ACTD) for 48 h. Neurons were 
preincubated for 1 h in CHX and ACTD before microinjections. The 
data represent the mean   SEM of three independent experiments. 
One-way ANOVA (df   5) followed by Sheffé’s test determined a 
statistical significant difference between A 1–42 in absence and 
presence of CHX and ACTD but not between CHX and ACTD 
treatment of non and A 1–42-injected neurons. *, P   0.01.524 The Journal of Cell Biology | Volume 156, Number 3, 2002
antibody, rabbit serum nor a mouse IgG, could neutralize
the pro-apoptotic properties of Bax (Fig. 5 B). Similarly,
these anti-Bax antibodies completely neutralized the A 1–42-
mediated neurotoxicity. In contrast, none of these antibod-
ies had any effect on recombinant active caspase-6–mediated
cell death. Therefore, these experiments show that anti-Bax
antibodies specifically inhibit Bax-mediated or A 1–42-medi-
ated cell death and indicate that A 1–42 induces cell death
through Bax activation. Together, these results implicate
Bax in A 1–42-mediated neuronal cell death.
p53 is involved in intracellular A 1–42-mediated 
neurotoxicity
Bax is transcriptionally regulated by p53; therefore, we
tested whether p53 activation was involved in intracellu-
lar A 1–42-mediated neurotoxicity. We chose to use the
p53
R273H dominant negative (p53
DN) mutant because it ef-
fectively inhibits p53 transcriptional activation of Bax (Au-
relio et al., 2000). Whereas the expression of p53 wild-type
(WT) or p53
DN does not induce neuronal apoptosis in ab-
sence or presence of A 1–40, the p53
DN, but not the p53
WT,
effectively inhibits A 1–42-mediated neurotoxicity (Fig. 6).
The inability of the p53
DN to inhibit the toxicity of Bax
when expressed from the CMV promoter of a cDNA con-
struct or to inhibit cell death by recombinant active caspase-6
attests to the specificity of the p53
DN against A 1–42-medi-
ated cell death. Together with the inhibition of A 1–42-
mediated neurotoxicity using Bax antibodies, these results
suggest that A 1–42 activates p53 which regulates Bax expres-
sion to induce cell death.
Figure 5. Inhibition of A 1–42-mediated neuronal cell death with 
Bcl-2 and Bax-neutralizing antibodies. (A) Cell death in neurons 
coinjected with A 1–42 and Bcl-2 or APP pCep4  eukaryotic cDNA 
expression episomal construct. *P   0.01. (B) Neuronal cell death 
in DTR alone (control), Bax cDNA, A 1–42 peptide, or recombinant 
active caspase-6 (R-Csp-6)-microinjected neurons in the absence 
( ) or presence of monoclonal Bax antibodies, 6A7 or 2D2, Bax 
polyclonal antisera, N-20, APP monoclonal antibody 22C11, 
mouse IgG, or rabbit nonimmune sera. Cells were incubated 24 h 
after microinjections. The data represent the mean   SEM of three 
independent experiments. One-way ANOVA (df   6) followed by 
Sheffé’s test determined the significance of the difference between 
the insult in absence and presence of the antibodies. *, P   0.01.
Figure 6. Inhibition of A 1–42-mediated neuronal cell death with 
p53 dominant negative R273H mutant but not p53 wild type. 
Neuronal cell death in DTR (Ctl), A 1–40 peptide, A 1–42 peptide,
R-Csp-6, or Bax cDNA alone ( ) or comicroinjected with cDNA 
expressing wild-type (WT) or dominant negative (DN) p53 in neurons. 
Microinjected cells were incubated 48 h. The data represent the 
mean   SEM of three independent experiments. One-way ANOVA 
(df   14) followed by Sheffé’s test showed a statistically significant 
difference between A 1–42 without and with p53
DN-injected neurons. 
*, P   0.01.Intracellular A  toxicity | Zhang et al. 525
Caspase inhibitors prevent A 1–42-mediated cell death
Previously, we have shown that serum deprivation induces
caspase-6–, but not caspase-3–mediated cell death in human
neurons (LeBlanc et al., 1999). To assess the role of caspases
in A 1–42-mediated neurotoxicity, we incubated A 1–42-
injected neurons in the presence or absence of various cas-
pase inhibitors. The results show that the pan caspase inhibitor,
Z-VAD-fmk, the caspase-6–like inhibitor, Z-VEID-fmk,
and the caspase-8–like inhibitor, Z-IETD-fmk, completely
prevent A 1–42-induced neuronal cell death (Fig. 7). In con-
trast, the caspase-1–like inhibitor, Z-YVAD-fmk and the
caspase-3–like inhibitor, Z-DEVD-fmk, do not inhibit
A 1–42-induced cell death. Therefore, the data show that
caspase-6– or caspase-8–like activities regulate A 1–42-medi-
ated neuronal apoptosis.
Discussion
The accumulation of intraneuronal A 42 before the appear-
ance of senile plaques and NFT in AD questions the rele-
vance of intraneuronal A 42 in neurons (Gouras et al., 2000;
D’Andrea et al., 2001). In the present manuscript, we show
that (a) very low levels of intracellular A 1–42, but not
A 1–40, A 42–1, or A 40–1, are selectively cytotoxic to human
neurons; (b) nonfibrillized A 1–42 peptide is as toxic as the
fibrillized peptide and toxicity may be attributable to the
formation of A 1–42 oligomers; and (c) A 1–42 toxicity is me-
diated through the p53 and Bax cell death pathway. There-
fore, our findings support the hypothesis that intracellular
accumulation of A 1–42 may be an initial cause of neuronal
dysfunction and loss in AD. Intracellular accumulation of
A 1–42 preceding other pathological lesions is observed not
only in AD (Gouras et al., 2000; D’Andrea et al., 2001), but
also in cells or transgenic mice expressing AD-associated
PS-1 mutations, APP mutations, or double APP/PS-1 muta-
tions (Masliah et al., 1996; Sudoh et al., 1998; Xia et al.,
1998; Chui et al., 1999; Petanceska et al., 2000; Wirths et
al., 2001) and in aging monkeys (Martin et al., 1994). Some
of these animal models have been shown to present behav-
ioral abnormalities or neurodegeneration before the appear-
ance of extracellular plaques (Chui et al., 1999; Hsia et al.,
1999). In addition, despite most studies showing that extra-
cellular A  deposition in senile plaques does not correlate
well with the severity of AD (Terry, 1999), analysis of total
A  levels in protein extracts from brains of well-ascertained
cognitively impaired patients reveals an elevation of both
A 40 and A 42 levels with increasing cognitive deficits
(Naslund et al., 2000). In the frontal cortex, the increased
A  levels precede significant NFT pathology. Therefore,
these data suggest that intracellular A  may be involved in
cognitive decline. Because a positive correlation exists be-
tween cognitive decline and loss of synaptophysin or neu-
rons, our results indicate that the intracellular A  could be
the initial insult leading to neuronal dysfunction or death in
AD (Masliah et al., 1989, 2001; Gomez-Isla et al., 1996).
The in vivo cytotoxicity of intracellular A 1–42 is sup-
ported by the results of LaFerla and colleagues (1995) who
showed that neurofilament L promoter-directed expression
of cytosolic A 1–42 results in neuronal cell death in mice
(LaFerla et al., 1996). Additionally, our experiments show
that levels of A 1–42 likely to be more physiological can rap-
idly induce cell death and that this toxicity is restricted to a
nonfibrillar form of A 1–42 peptide.
The extreme toxicity of intracellular A 1–42 raises some im-
portant questions. First, can A 1–42, which is made through
the secretory pathway, access the cytosol? Normally, it
should not. However, there are three possible modes of entry
of A 1–42 into the cytosol. Insoluble A 42 in the ER could ac-
cess the cytosol through the ER quality control system where
misfolded proteins are reverse translocated to the cytosol,
ubiquitinated, and degraded through the proteosome system
(Lippincott-Schwartz et al., 1988; Bonifacino et al., 1990;
Bonifacino and Lippincott-Schwartz, 1991; Greenfield et al.,
1999). In aging, the degradation of the A 1–42 could be com-
promised by a reduction of proteosomal activity thus result-
ing in cytosolic A 1–42 neurotoxicity (Merker et al., 2001).
Second, newly synthesized A 1–42 could be directed to endo-
somes/lysosomes either from the trans-Golgi or by endocyto-
sis of secreted peptide. In this situation, the A 1–42 would
have to be released in the cytosol through breakdown of
membrane or passive diffusion of the peptide from endo-
somes/lysosomes into the cytosol. Interestingly, it has been
shown that A 1–42, but not A 1–40, increases lysosomal mem-
brane permeability possibly resulting in leakage of the A 1–42
in the cytosol (Yang et al., 1998). Third, the secreted A 1–42
could passively diffuse back into the cytosol through the
plasma membrane. Many have reported the neuronal toxicity
of the extracellular A  peptides on primary and cell line sys-
tems (for review see Klein et al., 2001). In contrast to these
findings, we were unable to find toxicity of the extracellular
A 1–42 or A 1–40 in our cultures of human neurons despite
high concentrations of the peptides. However, we have pre-
Figure 7. Inhibition of A 1–42-mediated neuronal cell death with 
caspase inhibitors. Neurons were preincubated for 1 h in the presence 
of 5  M of each inhibitor, microinjected with A 1–42 peptide and 
incubated for 24 h in the presence of the inhibitors before revealing 
cell death of injected cells with TUNEL. The data represent the 
mean   SEM of three independent experiments. One-way ANOVA 
(df   11) followed by Sheffé’s test showed a statistically significant 
difference between A 1–42 and A 1–42   Z-VAD-fmk, Z-VEID-fmk, 
and Z-IETD-fmk. *, P   0.01.526 The Journal of Cell Biology | Volume 156, Number 3, 2002
viously shown that the amyloid peptides render neurons vul-
nerable to a secondary insult (Paradis et al., 1996). Others
have also observed this effect in human neuronal cultures
(Mattson et al., 1992). Possibly, the secondary stress in-
creases A  receptors or endocytosis or alters the plasma
membrane permeability resulting in the diffusion of the ex-
tracellular A 1–42 peptide inside the cell. However, this latter
possibility is unlikely to be a primary cause of AD, as intra-
cellular A 1–42 accumulation precedes senile plaques but nev-
ertheless could contribute to a secondary round of cell death
after the deposition of extracellular amyloid.
The selective toxicity of A 1–42 compared with A 1–40
poses another interesting problem: the extracellular A  pep-
tide toxicity has been attributed to the fibrillar, protofibril-
lar, or aggregating properties of A  (for review see Klein et
al., 2001). For intracellular A 1–42 toxicity, there exists three
possibilities. First, it could be that the extra two amino acids
on A 1–42 are responsible for inducing toxicity. Second, as
has previously been suggested, amyloid fibrils could be the
toxic molecules. However, both less toxic A 1–40 and ex-
tremely toxic A 1–42 form significant amounts of fibrils and
nonfibrillized A 1–42 is still very toxic. Third, the oligomers
observed by Western blot analysis in the nonfibrillized and
fibrillized A 1–42 could be responsible for cell death (Walsh
et al., 1999). Furthermore, it remains a possibility that the
forms observed by electron microscopy and by Western blot
analysis change when microinjected in neurons due to asso-
ciation with certain cytosolic factors (Walsh et al., 1999;
Nilsberth et al., 2001). Therefore, much work will be re-
quired to elucidate the toxic structure of the A 1–42 peptides.
We further show that A 1–42 mediates neurotoxicity
through the known p53 and Bax cell death pathway. p53 ex-
pression increases in the transgenic neurons of cytosolically
expressed A 1–42 and in AD neurons (LaFerla et al., 1996;
de la Monte et al., 1997, 1998; Kitamura et al., 1997; Seidl
et al., 1999). In addition, synthetic p53 inhibitors can pre-
vent extracellular A  mediated toxicity of hippocampal
neuron cultures (Culmsee et al., 2001). Extracellular A  can
upregulate Bax expression or require Bax to mediate cyto-
toxicity (Paradis et al., 1996; Selznick et al., 2000; Culmsee
et al., 2001). Furthermore, Bax protein levels increase in AD
(MacGibbon et al., 1997; Nagy and Esiri, 1997; Su et al.,
1997; Tortosa et al., 1998; Giannakopoulos et al., 1999), al-
though this was not confirmed by all studies (Engidawork et
al., 2001). Therefore, the identification of the role of the
p53–Bax cell death pathway in intracellular A 1–42-mediated
neurotoxicity reveals additional therapeutic targets that
could be used against AD. Because p53 is activated through
phosphorylation, the results suggest that A 1–42 induces a
kinase or inhibits a phosphatase responsible for this phos-
phorylation. Given the known importance of tau hyper-
phosphorylation in AD, one wonders whether the activation
of p53 could be linked to the phosphorylation of tau
through intracellular A 1–42 induction of kinase activity.
The mechanism by which p53 is activated by intracellular
A 1–42 remains to be elucidated. It is interesting to note that
A 1–42 interacts with ERAB, an intracellular ER and mito-
chondria-localized member of the alcohol dehydrogenase
family (Yan et al., 1997). In transfected Cos cells, ERAB fa-
cilitates the toxicity of extracellular A 1–42 and APP
V717G
mutant (Yan et al., 1999). Whether ERAB is involved in cy-
tosolic A 1–42 toxicity remains to be determined but since
ERAB is localized to mitochondria and ER, it is unlikely to
have access to the injected A 1–42 unless mitochondrial
ERAB is released into the cytosol during apoptosis as are
many other mitochondrial factors.
It is well known that Bax activates caspases by promoting
the release of mitochondrial cytochrome c, which forms an
apoptosome with a number of other factors including
caspases (Adrain and Martin, 2001). The caspase-9 has spe-
cifically been shown to be activated by cytochrome c and
further activate caspase-3. Our result showing that the cas-
pase-6 and -8, but not the caspase-3 inhibitors, prevent A 1–42
toxicity is surprising. The lack of involvement of caspase-3
is likely due to the fact that these neurons contain high levels
of inhibitor of apoptosis proteins known to inhibit caspase-3
(Zhang and LeBlanc; unpublished data). These results are
consistent with our previous observation that caspase-6, but
not caspase-3, is activated in serum-deprived primary hu-
man neurons and that only recombinant active caspase-6 in-
duces apoptosis of human primary neurons (LeBlanc et al.,
1999; Zhang et al., 2000). Because little is known of cas-
pase-6 regulation, much more work will be required to un-
derstand how caspase-6 is activated in the presence of intra-
cellular A 1–42.
Uncovering the acute human neuronal toxicity of intracel-
lular A 1–42 questions the validity of the currently developed
therapies against extracellular amyloid in AD. If intracellular
A 1–42 precedes extracellular amyloid deposits, then anti-
amyloid therapies need to be cell permeable. Otherwise, they
may have little effect on the prevention or early treatment of
AD but could be beneficial to prevent further damage in-
curred by the extracellular amyloid. However, if the intracel-
lular A 1–42 is a consequence of extracellular amyloid depos-
its, then these therapies would presumably be advantageous
to AD patients. Attempts directed toward the inhibition of
the secretases responsible for the production of A 1–42
should also have a favorable impact on the disease assuming
that it is only A 1–42 that is the problem in AD and not an
underlying general problem with the secretory pathway re-
sulting in the misfolding and cytosolic accumulation of
other insoluble proteins. Our study indicates that in addi-
tion to the antiamyloid strategies, antineuronal cell death
therapies against p53, Bax, or caspases could be extremely
valuable in preventing neuronal loss in AD.
Materials and methods
cDNA clones
Human Bcl-2 cDNA was obtained from Dr. Walter Nishioka (Vical, Inc.).
Bax cDNA was amplified from a human neuron cDNA library (Bounhar et
al., 2001). APP695 cDNA in pCep4  was obtained from Steve Younkin
(Mayo Clinic, Jacksonville, FL). The cDNAs were cloned into pCep4  (In-
vitrogen). The p53 wild-type and p53
R273H dominant negative cDNAs were
produced by Arnold Levine, and were cloned in the pCMV-NEO vector
(Hinds et al., 1990). These cDNAs were purified through GlassMAX
TM
(GIBCO BRL) and diluted at 30 ng/ l in PBS before the microinjections.
Primers were designed to amplify secreted and cytosolic A 1–40 and
A 1–42 from APP695. These primers amplify the entire A  sequence with an
additional methionine ATG codon at the 5  end and a stop codon at the 3 
end to ensure translation. Cytosolic A  was amplified with the A 1–40/42
forward primer 5 -TCA CTC GAG AAT GGA TGC AGA ATT CCG ACA
T-3  (contains a built-in 5  XhoI site) and A 1–42 reverse primer 5 -ATGIntracellular A  toxicity | Zhang et al. 527
GAT CCT TAC GCT ATG ACA ACA CCG AA-3  (has a 3  BamH1 site) or
A 1–40 reverse primer 5 -TCG ATC CTT AGA CAA CAC CGC CCA CCA
TG-3  (has a 3  BamH1 site). Secreted A  was made by linking the APP
signal peptide (SP) to the A  sequence. The SP was amplified with APP-
SP1 forward primer, 5 -TTA CTC GAG ATG CTG CCC GGT TTG GCA-3 
(contains a 5  XhoI site) and APP-SP2 reverse primer, 5 -GGA ATT CTG
CAT CCA TCG CCC GAG CCG TCC AGG C-3  (contains a 3  EcoR1 site).
A ligation between EcoR1- cleaved PCR-amplified A  coding sequence
and the EcoR1-cleaved SP sequence was reamplified with the A 1–40/42 for-
ward primer and A 1–40 or A 1–42 reverse primers. The PCR-amplified SP
and A  sequence were cloned into the prokaryotic pBSKII and eukaryotic
episomal pCep4  vectors through the XhoI/BamHI restriction sites. All
clones were restriction mapped and sequenced before use.
Neutralizing Bax antibodies
Monoclonal anti-Bax 6A7 (amino acids 12–24; PharMingen) and 2D2
(amino acids 3–16; Trevigen), polyclonal anti-Bax N-20 (Santa Cruz Bio-
technology, Inc.), monoclonal anti-APP 22C11 (Roche), mouse IgG, or
rabbit sera were diluted at 50  g/ml (for 6A7, 2D2, mouse IgG, and
22C11) or 25  g/ml (for polyclonal anti-Bax and rabbit sera) in PBS before
use. A toxicity curve was done to determine these concentrations as the
highest nontoxic concentrations that can be injected in neurons.
Cell cultures
Primary cultures of human neurons and astrocytes were prepared from 11–
17-wk-old fetal brains as described previously (LeBlanc, 1995). The
McGill University Institutional Review Board (Montréal, Québec, Canada)
has approved this procedure following Canadian Institutes of Health and
National Institutes of Health ethical guidelines. Brain tissues were dissoci-
ated with 0.25% trypsin (GIBCO BRL) in PBS at 37 C for 15 min. The
trypsin was inactivated with 10% decomplemented FBS (HyClone). The
dissociated cells were triturated in 0.1 mg/ml DNaseI (GIBCO BRL), fil-
tered successively through 130  m nylon mesh (Sefar Canada, Inc.) and
Falcon 70- m cell strainers (Becton Dickinson), and centrifuged at 5,000 g
for 10 min at 10 C to pellet the cells. The cell pellet was washed once with
PBS and once with MEM (GIBCO BRL) in Earle’s balanced salt solution
containing 0.225% sodium bicarbonate, 1 mM sodium pyruvate, 2 mM
L-glutamine, 0.1% dextrose, antibiotic Pen-Strep (all from GIBCO BRL),
and 5% decomplemented FBS. The cells were plated at a density of 3  
10
6 cells/ml on poly-L-lysine–coated ACLAR™ (Cat. No., 33C; thickness,
0.5 mm; Allied Chemical) coverslips. Neuron cultures were treated succes-
sively three times with 1 mM fluorodeoxyuridine (GIBCO BRL) at feeding,
and subsequently every week to prevent proliferation of dividing cells. In
general, the neurons attach to the coverslips within 24 h and develop
dense neuritic networks within 3 d. The cultures contain 90–95% neurons
and 5–10% astrocytes (LeBlanc, 1995). Microinjections or treatments were
performed 10 d after plating for neurons and astrocytes.
Human neuroblastoma M17 cells were obtained from Dr. J. Biedler
(Cellular Biochemistry and Genetics, New York, NY) and cultured on
ACLAR™ coverslips at 10
6 cells/ml in OPTI-MEM (GIBCO BRL) containing
5% FBS. Human teratocarcinoma NT2 (Stratagene) and neuroblastoma La-
N-1 cells, a gift from Dr. L. Culp (Case Western Reserve University, Cleve-
land, OH), were cultured on ACLAR™ coverslips at 10
6 cells/ml in DME
(GIBCO BRL) containing 10% FBS. BHK cells, a gift from William Bowers
(University of Rochester, Rochester, NY), and the mice NIH3T3 fibroblasts,
a gift from Dr. Stephane Richard (McGill University, Montréal, Québec,
Canada) were grown in DME and 10% FBS.
A  peptides
Initially (for Fig. 1), A  peptides (Bachem) were dissolved in sterile distilled
water at 25  M and incubated at 37 C for 5 d. The peptides’ stock solu-
tions were frozen and diluted in PBS immediately before microinjection.
Thereafter, nonfibrillar A  peptides (American Peptide Co.) were disaggre-
gated at 25  M in 5 mM Tris buffer pH 7.4, an aliquot diluted to 0.25  M
and immediately frozen at  20 C in aliquots of 50  l. The remaining 25-
 M solution was incubated at 37 C in Eppendorf tubes with continuous
mixing by inversion to fibrillize the peptides. After incubation, the samples
were removed, vortexed, sonicated twice for 1 min in a bath type sonica-
tor (ELMA GmbH & Co. KG), and frozen at  20 C in 50  l aliquots. Each
aliquot was used once to avoid possible effects of freeze and thaw cycles.
Electron microscopy
A 3- l aliquot of A  peptide was placed on freshly cleaved mica plates
(BioForce Laboratory, Inc.). The specimens were air dried and subse-
quently transferred to a Balzers High-Vacuum Freeze-Etch Unit (model
301) under a 1.3   10
 4 Pa vacuum. The specimens were shadowed with
platinum (BAL-TEC EM-Technology and Application, NH) at a 30  angle
and coated with a carbon film platinum (BAL-TEC EM-Technology and Ap-
plication). The replicas were detached from the mica by flotation in deion-
ized water and transferred onto a 300-mesh grid (Canemco, Inc.). The
grids were examined with a Joel 200FX transmission electron microscope
(Joel) at 21,000  magnification.
Western blot analysis of A  peptides
Nonfibrillar and fibrillar forms of A 1–40 and A 1–42 (5  g) were added to
sample buffer and electrophoresed on a triple layer (4%, 10%, 16.5%)
Tris-Tricine gel at 50 V for 1 h followed by 70 V for 16 h (Schagger and
Von Jagow, 1987). The proteins were transferred to Immobilon-P PVDF
Membrane (Millipore) at 200 milliamps for 2 h. The membrane was
blocked by 5% nonfat milk in Tris buffered saline with 0.1% Tween 20
(TBST) at room temperature for 1 h, incubated with a 1/100 dilution of the
anti-A 1–17 antibody 6E10 (Signet) and detected by chemiluminescence.
Microinjection
Thin-walled Borosilicate glass capillaries (OD 1.0 mm, ID 0.5 mm) with
microfilament (MTW100F-4; World Precision Instrument) were pulled
with a Flaming/Brown Micropipette Puller (P-87; Sutter) to obtain injection
needles with a tip diameter of  0.5  m. Microinjections were performed
in the cytosol of each cell using the Eppendorf Microinjector 5246 and
Burleigh Micromanipulator MIS-5000. Human neurons were injected with
25 pl/shot at an injection pressure of 100 hPa, a compensation pressure of
50 hPa, and an injection time of 0.1 s. Human astrocytes, M17, NT2, La-
N-1, BHK, and NIH 3T3 cells were injected with 8 pl/shot at an injection
pressure of 50 hPa, a compensation pressure of 30 hPa and an injection
time of 0.1 s. The diluted peptides were injected at the indicated concen-
trations with 100  g/ml DTR (MW: 3000; Molecular Probes) as a fluores-
cent marker to recognize the injected cells. Approximately 90% neurons
and NT2 cells, and 50% astrocytes, M17, La-N-1, BHK, and NIH 3T3 cells
survive the injections for at least 16 d.
Measurement of neuronal apoptosis
Cells were fixed in freshly prepared 4% paraformaldehyde/4% sucrose for
20 min at room temperature and permeabilized in 0.1% Triton X-100,
0.1% sodium citrate on ice for 2 min. Terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick end labeling (TUNEL) was performed using the
In situ Cell Death Detection Kit I as described by the manufacturer
(Roche). The percentage of cell death was determined as the ratio of the
number of DTR-TUNEL–double positive cells over the total number of
DTR-positive cells.
Hoechst staining was used to recognize cell nuclei and detect apoptotic
nuclear condensation and fragmentation. Hoechst dye (Intergen) was dis-
solved in sterile distilled water at 200  g/ml and diluted 500 times in PBS
immediately before staining. After the incubation for TUNEL staining, cells
were washed three times for 10 min each in PBS, treated with the diluted
Hoechst dye for 15 min at room temperature (in the dark), washed three
times for 10 min each in PBS, washed once in water for 5 min, and
mounted with Immunon™
 mounting medium (Shandon) onto glass slides
to be observed under the fluorescence microscope.
Treatment with caspase inhibitors, cycloheximide,
and actinomycin D
Caspase pan inhibitor, Z-Valine-Alanine-Aspartic acid-fluoromethylketone
(Z-VAD-fmk) (Biomol), caspase-1 inhibitor, Z-Tyrosine-Valine-Alanine-
Aspartic acid-fmk (Z-YVAD-fmk), caspase-6 inhibitor, Z-Valine-Glu-
tamic acid-Isoleucine-Aspartic acid-fmk (Z-VEID-fmk), caspase-3 inhibitor,
Z-Aspartic acid-Glutamic acid-Valine-Aspartic acid-fmk (Z-DEVD-fmk),
and caspase-8 inhibitor, Z-Isoleucine-Glutamic acid-Threomine-Aspartic
acid-fmk (Z-IETD-fmk) (Sigma-Aldrich), were dissolved in 100% DMSO
(Sigma-Aldrich) at 20 mM and were diluted at 5  M into culture media im-
mediately before use. Stock solutions of 5 mg/ml cycloheximide (Sigma-
Aldrich) and 200  M actinomycin D (Sigma-Aldrich) were made in sterile
distilled water and diluted to 5  g/ml for cycloheximide and 5  M for ac-
tinomycin D in the culture media immediately before use. The media was
changed every 48 h.
Statistical evaluation
One-way or two-way analyses of variance (ANOVAs) with post hoc tests
(Statview 5.01) determined the statistical significance of the difference be-
tween treatments. The Dunnett’s test was used when comparing several
groups with one certain group (control), for example, comparison between
different treatment groups vs. untreated group. The Sheffé’s test was ap-
plied when comparing between every other group, for example, compari-528 The Journal of Cell Biology | Volume 156, Number 3, 2002
son between each treatment group. A P value of  0.05 was taken as the
criteria for statistical significance.
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